HCW Biologics issues pre-funded warrant agreement for common stock purchase

HCW Biologics Inc. filed a pre-funded warrant form allowing holders to purchase common shares at a specified exercise price beginning in 2026. The warrant issuance represents a capital raising mechanism typically used in equity financings for growth-stage biotech companies.